The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Open accessAbstract
Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.Findings From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).Interpretation Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.Funding Acerta Pharma, a member of the AstraZeneca Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, ibrutinib and the more selective BTK inhibitor acalabrutinib 39 have shown beneficial effects in patients with MCL and have received US Food and Drug Administration approval for this indication.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558
Barf, T. A., Covey, T. M., Izumi, R. E., van de Kar, B., Gulrajani, M., van Lith, B., Hoek, M. E.-V., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 399
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 276
Cited by
Sorted by citations
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Self-citationRole of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M. J., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A. H., Monticelli, M. A., Roshon, M. J., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 350
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 315
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 294
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Jain, P., & Wang, M. L. (2019) · American Journal of Hematology · doi:10.1002/ajh.25487 · Cited by 282
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 274
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2020) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 276
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Xiao, L., Salem, J., Clauß, S., Hanley, A., Bapat, A. C., Hulsmans, M., Iwamoto, Y., Wojtkiewicz, G. R., Çetinbaş, M., Schloss, M. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049210 · Cited by 254
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Chávez, J. C., Bachmeier, C. A., & Kharfan‐Dabaja, M. A. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719841581 · Cited by 225
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 214
Update on mantle cell lymphoma
Maddocks, K. J. (2018) · Blood · doi:10.1182/blood-2018-03-791392 · Cited by 211
Bruton Tyrosine Kinase Inhibitors
Burger, J. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000412 · Cited by 200
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A., Jacobs, M. T., McGuirk, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01797 · Cited by 195
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
Awan, F. T., Schuh, A., Brown, J. R., Furman, R. R., Pagel, J. M., Hillmen, P., Stephens, D. M., Woyach, J. A., Бибикова, Е., Charuworn, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030007 · Cited by 188
Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3703 · Cited by 185
Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., et al. (2022) · Blood · doi:10.1182/blood.2021014162 · Cited by 178
Owen, R. G., McCarthy, H. O., Rule, S. A., D’Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30210-8 · Cited by 167
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 159
Dreyling, M. H., Doorduijn, J. K., Giné, E., Jerkeman, M., Walewski, J. A., Hutchings, M., Mey, U., Riise, J., Trněný, M., Vergote, V., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00184-3 · Cited by 164
Jain, P., & Wang, M. L. (2022) · American Journal of Hematology · doi:10.1002/ajh.26523 · Cited by 156
Eyre, T. A., Walter, H. S., Iyengar, S., Follows, G., Cross, M., Fox, C. P., Hodson, A., Coats, J. T., Narat, S., Morley, N. J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198812 · Cited by 142
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Kumar, A. A., Sha, F., Toure, A., Doǧan, A., Ni, A., Batlevi, C. L., Palomba, M. L., Portlock, C. S., Straus, D. J., Noy, A., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0209-5 · Cited by 126
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Ruan, J., Martin, P., Christos, P. J., Cerchietti, L. C. A., Tam, W., Shah, B. D., Schuster, S. J., Rodriguez, A., Hyman, D. M., Calvo-Vidal, M. N., et al. (2018) · Blood · doi:10.1182/blood-2018-07-859769 · Cited by 124
Watterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Sibaud, V., Beylot-Barry, M., Protin, C. A., Vigarios, É., Récher, C., & Ysebaert, L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00535-x · Cited by 124
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ahmed, M., Ghorab, A., Zhang, L., Ok, C. Y., Li, S., Hagemeister, F. B., Zeng, D., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15567 · Cited by 121
Wang, M. L., Rule, S. A., Zinzani, P. L., Goy, A. H., Casasnovas, O., Smith, S. D., Damaj, G. L., Doorduijn, J. K., Lamy, T., Morschhauser, F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0575-9 · Cited by 118
Silkenstedt, E., Salles, G. A., Campo, E., & Dreyling, M. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02705-8 · Cited by 129
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Tam, C. S. L., Opat, S., Simpson, D., Cull, G., Munoz, J. L., Phillips, T. J., Kim, W. S., Rule, S. A., Atwal, S. K., Wei, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004074 · Cited by 105
Nakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Visco, C., Rocco, A. D., Evangelista, A., Quaglia, F. M., Tisi, M. C., Morello, L., Zilioli, V. R., Rusconi, C., Hohaus, S., Sciarra, R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01013-3 · Cited by 102
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
von Hundelshausen, P., & Siess, W. (2021) · Cancers · doi:10.3390/cancers13051103 · Cited by 100
Owen, C., Berinstein, N. L., Christofides, A., & Sehn, L. H. (2019) · Current Oncology · doi:10.3747/co.26.4345 · Cited by 101
Pattarabanjird, T., Li, C., & McNamara, C. A. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.01.006 · Cited by 99
Liclican, A. C., Serafini, L., Xing, W., Czerwieniec, G. A., Steiner, B. H., Wang, T., Brendza, K. M., Lutz, J. D., Keegan, K. S., Ray, A. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129531 · Cited by 101
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Gu, D., Tang, H., Wu, J., Li, J., & Miao, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01049-7 · Cited by 100
Wang, Y., Luan, Z., Zhao, C., Bai, C., & Yang, K. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105136 · Cited by 95
Efficient C–H Amination Catalysis Using Nickel-Dipyrrin Complexes
Dong, Y., Clarke, R. M., Porter, G. J., & Betley, T. A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02126 · Cited by 95
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Shirley, M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00857-8 · Cited by 92
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Jain, P., Zhao, S., Lee, H. J., Hill, H. A., Ok, C. Y., Kanagal‐Shamanna, R., Hagemeister, F. B., Fowler, N. H., Fayad, L., Yao, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01797 · Cited by 84
de Groen, R. A. L., Schrader, A. M. R., Kersten, M. J., Pals, S. T., & Vermaat, J. S. P. (2019) · Haematologica · doi:10.3324/haematol.2019.227272 · Cited by 86
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Tam, C. S. L., Dimopoulos, M. A., García‐Sánz, R., Trotman, J., Opat, S., Roberts, A. W., Owen, R. G., Song, Y., Xu, W. L., Zhu, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005621 · Cited by 86
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Martin, P., Bartlett, N. L., Blum, K. A., Park, S. I., Maddocks, K. J., Ruan, J., Ridling, L., Dittus, C. E., Chen, Z., Huang, X., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886457 · Cited by 84
Minson, A. G., Hamad, N., Cheah, C. Y., Tam, C. S. L., Blombery, P. A., Westerman, D., Ritchie, D., Morgan, H., Holzwart, N., Lade, S., et al. (2023) · Blood · doi:10.1182/blood.2023021306 · Cited by 87
Efremov, D. G., Turkalj, S., & Laurenti, L. (2020) · Cancers · doi:10.3390/cancers12061396 · Cited by 85
Qin, J., Johnstone, T. G., Baturevych, A., Hause, R. J., Ragan, S. P., Clouser, C. R., Jones, J. C., Ponce, R. A., Krejsa, C. M., Salmon, R. A., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000307 · Cited by 79
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Balaji, S., Ahmed, M., Lorence, E., Yan, F., Nomie, K. J., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0621-5 · Cited by 77
Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
McCulloch, R., Visco, C., Eyre, T. A., Frewin, R., Phillips, N., Tucker, D. L., Quaglia, F. M., McMillan, A., Lambert, J., Crosbie, N., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16416 · Cited by 76
Therapeutic options for relapsed/refractory mantle cell lymphoma
Eyre, T. A., Cheah, C. Y., & Wang, M. L. (2021) · Blood · doi:10.1182/blood.2021013326 · Cited by 75
Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Бибикова, Е., Sun, H., Gohdes, M. A., Cardinal, K. A., Sanghvi, M., & Slatter, J. G. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084459 · Cited by 72
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Wang, M. L., Belada, D., Belada, D., Song, Y., Jurczak, W. J., Kahl, B. S., Paludo, J., Chu, M. P., Kryachok, I., Fogliatto, L., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00690 · Cited by 78
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Mian, A., & Hill, B. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1889510 · Cited by 68
BTK inhibitors: past, present, and future
Cool, A., Nong, T., Montoya, S., & Taylor, J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.06.006 · Cited by 63
Alexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 71
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
Bhat, S. A., Gambril, J. A., Azali, L., Chen, S. T., Rosen, L., Palettas, M. S., Wiczer, T. E., Kalathoor, S., Zhao, Q., Rogers, K. A., et al. (2022) · Blood · doi:10.1182/blood.2022016953 · Cited by 66
Jain, P., Romaguera, J. E., Srour, S. A., Lee, H. J., Hagemeister, F. B., Westin, J. R., Fayad, L., Samaniego, F., Badillo, M., Zhang, L., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15411 · Cited by 64
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2
Nicolson, P. L. R., Nock, S. H., Hinds, J., Garcia‐Quintanilla, L., Smith, C. W., Campos, J., Brill, A. G., Pike, J. A., Khan, A. O., Poulter, N. S., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218545 · Cited by 64
Hou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 64
Furman, R. R., Byrd, J. C., Owen, R. G., O'Brien, S. M., Brown, J. R., Hillmen, P., Stephens, D. M., Chernyukhin, N., Lezhava, T., Hamdy, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01252-y · Cited by 64
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches
Silkenstedt, E., & Dreyling, M. H. (2023) · Hematological Oncology · doi:10.1002/hon.3149 · Cited by 62
Kumar, A. A., Soumerai, J. D., Abramson, J. S., Barnes, J. A., Caron, P. C., Chhabra, S., Chabowska, M., Doǧan, A., Falchi, L., Grieve, C., et al. (2024) · Blood · doi:10.1182/blood.2024025563 · Cited by 59
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Valla, K., Flowers, C. R., & Koff, J. L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1482273 · Cited by 60
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., Linton, K., & Dreyling, M. H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17419 · Cited by 59
Wang, M. L., Jain, P., Zhao, S., Lee, H. J., Nastoupil, L. J., Fayad, L., Ok, C. Y., Kanagal‐Shamanna, R., Hill, H. A., Yao, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00638-0 · Cited by 56
Development of BTK inhibitors for the treatment of B-cell malignancies
Kim, H.-O. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01124-1 · Cited by 60
Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
Saul, S., & Einav, S. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00343 · Cited by 56
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Wu, X., Stenson, M. J., Abeykoon, J. P., Nowakowski, K. E., Zhang, L., Lawson, J., Wellik, L. E., Li, Y., Krull, J. E., Wenzl, K., et al. (2019) · Blood · doi:10.1182/blood.2018874560 · Cited by 55
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
Iovino, L., & Shadman, M. S. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0715-5 · Cited by 55
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Abbas, H. A., & Wierda, W. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668162 · Cited by 54
Zanubrutinib: past, present, and future
Tam, C. S. L., Munoz, J. L., Seymour, J. F., & Opat, S. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00902-x · Cited by 58
Zhu, S., Gokhale, S., Jung, J., Spirollari, E., Tsai, J., Arceo, J., Wu, B. W., Victor, E., & Xie, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727531 · Cited by 54
Clinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Catalytic Asymmetric Synthesis of α‐Arylpyrrolidines and Benzo‐fused Nitrogen Heterocycles
Dai, X., Engl, O. D., León, T., & Buchwald, S. L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201814331 · Cited by 53
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 53
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Jain, P., Dreyling, M. H., Seymour, J. F., & Wang, M. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02287 · Cited by 53
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Profitós-Pelejà, N., Santos, J. C., Marín‐Niebla, A., Roué, G., & Ribeiro, M. L. (2022) · Cancers · doi:10.3390/cancers14040860 · Cited by 53
Emerging therapies in mantle cell lymphoma
Hanel, W. G., & Epperla, N. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00914-1 · Cited by 50
Guideline for the management of mantle cell lymphoma
McKay, P., Leach, M., Jackson, B., Robinson, S. P., & Rule, S. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15283 · Cited by 50
New Directions for Mantle Cell Lymphoma in 2022
Kumar, A. A., Eyre, T. A., Lewis, K. L., Thompson, M. C., & Cheah, C. Y. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349509 · Cited by 49
Garg, N., Padron, E., Rammohan, K. W., & Goodman, C. F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206139 · Cited by 54
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
Sestier, M., Hillis, C., Fraser, G. A. M., & Leong, D. P. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01102-1 · Cited by 52
Current overview and treatment of mantle cell lymphoma
Schieber, M., Gordon, L. I., & Karmali, R. (2018) · F1000Research · doi:10.12688/f1000research.14122.1 · Cited by 47
Zhou, D., Podoll, T., Xu, Y., Moorthy, G., Vishwanathan, K., Ware, J. A., Slatter, J. G., & Al-Huniti, N. H. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12408 · Cited by 48
Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
da Cunha‐Bang, C., & Niemann, C. U. (2018) · Drugs · doi:10.1007/s40265-018-1003-6 · Cited by 47
CAR T-Cell Therapy in the Older Person: Indications and Risks
Shouse, G., Danilov, A. V., & Artz, A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01272-6 · Cited by 44
Mantle cell lymphoma and its management: where are we now?
Ladha, A., Zhao, J., Epner, E. M., & Pu, J. J. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0126-0 · Cited by 44
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, S., Mursal, M., Verma, G., Hasan, S. S., & Khan, M. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176484 · Cited by 41
Salles, G. A., Gopal, A. K., Minnema, M. C., Wakamiya, K., Feng, H., Schecter, J. M., & Wang, M. L. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.013 · Cited by 42
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 43
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Chen, S. T., Azali, L., Rosen, L., Zhao, Q., Wiczer, T. E., Palettas, M. S., Gambril, J. A., Kola-Kehinde, O. O., Ruz, P., Kalathoor, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01302-7 · Cited by 40
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Dong, R., Yan, Y., Zeng, X., Lin, N., & Tan, B. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s377697 · Cited by 39
The potential of pirtobrutinib in multiple B-cell malignancies
Jensen, J. L., Mato, A. R., Peña, C., Roeker, L. E., & Coombs, C. C. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221101697 · Cited by 40
Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
Fares, A. A., Uribe, C. R. C., Martinez, D., Rehman, T. U., Rondon, C. S., & Sandoval-Sus, J. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042208 · Cited by 39
Metadata
- Authors
- Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Covey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G., & Jurczak, W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Plymouth (GB)
- University of Bologna (IT)
- Hackensack University Medical Center (US)
- Inserm (FR)
- University of Washington (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Erasmus MC (NL)
- Centre Hospitalier Universitaire de Rennes (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Clinica Universidad de Navarra (ES)
- Moffitt Cancer Center (US)
- Cancer Research UK (GB)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Jagiellonian University (PL)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 391
- Issue
- 10121
- Pages
- 659-667
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7864374
- OpenAlex
- W2774522106
- Cited by
- 453
- References
- 23
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 51 · 2023: 49 · 2022: 59 · 2021: 60 · 2020: 63 · 2019: 64 · 2018: 34
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- PEARL (University of Plymouth) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- ePrints Soton (University of Southampton) (submittedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- AstraZeneca
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- acalabrutinib, mantle cell lymphoma, relapsed/refractory lymphoma, BTK inhibitors, overall response rate, complete response, progression-free survival, overall survival, adverse events, neutropenia, drug safety, oral targeted therapy, treatment durability, hemorrhage
- MeSH terms
- Aged, Benzamides, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pyrazines, Recurrence, Survival Analysis, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
